Biovail Cardizem XL NDA
This article was originally published in Pharmaceutical Approvals Monthly
Biovail submits NDA for the calcium channel blocker Cardizem XL Aug. 23 for treatment of hypertension. The once-daily, graded-release diltiazem formulation "uses a unique dissolution profile, in conjunction with nighttime dosing, to address the body's typical 24-hour circadian variation in blood pressure," the firm says. In Phase III trials comparing nighttime and daytime administration, evening use resulted in "statistically significant and clinically meaningful reductions in diastolic and systolic blood pressure" between 4 a.m. and 12 noon, "the time of day when patients are at the greatest risk of having an adverse cardiac event," the firm said. Biovail received approval in January 2000 for an earlier generation extended-release diltiazem without nighttime dosing. That formulation was never marketed
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.